Search results
Results from the WOW.Com Content Network
HER2 is so named because it has a similar structure to human epidermal growth factor receptor, or HER1. Neu is so named because it was derived from a rodent glioblastoma cell line, a type of neural tumor. ErbB-2 was named for its similarity to ErbB (avian erythroblastosis oncogene B), the oncogene later found to code for EGFR.
Dennis Joseph Slamon (born August 6, 1948), [1] [2] is an American oncologist and chief of the division of Hematology-Oncology at UCLA.He is best known for his work identifying the HER2/neu oncogene that is amplified in 25–33% of breast cancer patients and the resulting treatment trastuzumab.
H. Michael Shepard (born 1949) is an American cancer researcher who was awarded the 2007 Harvard Medical School Warren Alpert Foundation Prize and the 2019 Lasker Clinical research award, which he shared with Dennis Slamon and Axel Ullrich for their development of Herceptin [1]
Teleplay writer Vivienne Radkoff had the story for about seven years before it was completed. It is an adaptation of Robert Bazell's book HER-2: The Making of Herceptin, a Revolutionary Treatment for Breast Cancer. The film was the first mainstream feature film to be scored as a solo project by composer Halli Cauthery.
The HER2 gene (also known as HER2/neu and ErbB2 gene) is amplified in 20–30% of early-stage breast cancers. [44] Trastuzumab is a monoclonal antibody targeting HER2, inducing an immune-mediated response that causes internalization and recycling of HER2. It may also upregulate cell cycle inhibitors such as p21 Waf1 and p27 Kip1. [58]
The threshold level for hormone receptor positivity was changed in 2010 and now requires more than 1% positive tumor nuclei are found in the tumor sample. [14] Newer techniques for categorising breast cancer are based on gene expression in the tumor which classifies breast cancer into: [15] [16] luminal A (HR+/HER2-) 68%; luminal B (HR+/HER2+) 10%
a phase III trial for HER2+ gastric cancer compares T-DM1 to physician's choice of taxane (docetaxel or paclitaxel). [35] On 22 October 2015, Roche and co-developer ImmunoGen disclosed that trastuzumab emtansine had failed to meet its primary endpoint in the Phase II/III GATSBY trial investigating the second line treatment of HER2 -positive ...
This is an accepted version of this page This is the latest accepted revision, reviewed on 19 January 2025. African-American woman (1920–1951), source of HeLa immortal cell line "Lacks" redirects here. For other uses, see Lack. Henrietta Lacks Lacks c. 1945–1951. Born Loretta Pleasant (1920-08-01) August 1, 1920 Roanoke, Virginia, U.S. Died October 4, 1951 (1951-10-04) (aged 31) Baltimore ...